Subscribe

Benjamin L. Schlechter, MD

Articles by Benjamin L. Schlechter, MD

Benjamin L. Schlechter, MD, on TAC01-HER2 in HER2-Positive Solid Tumors

ByBenjamin L. Schlechter, MD

November 1st 2022

Schlechter discussed the potential advantages of TAC01-HER2 over current standards of care.

Benjamin L. Schlechter, MD, on Addressing Unmet Needs in HER2 Positive Solid Tumors

ByBenjamin L. Schlechter, MD

October 31st 2022

Schlechter discussed the design of the TACTIC-2 clinical trial for patients with HER2-positive solid tumors.

Latest Updated Articles

Benjamin L. Schlechter, MD, on Addressing Unmet Needs in HER2 Positive Solid Tumors
Published: October 31st 2022 | Updated:
Benjamin L. Schlechter, MD, on TAC01-HER2 in HER2-Positive Solid Tumors
Published: November 1st 2022 | Updated:

Trending on CGTlive®

Sangamo Starts Putting BLA for Fabry Disease Gene Therapy Isa-Vec in Front of FDA

The Implications of the Final Data From Hemgenix’s HOPE-B Trial

What the Field of Cell and Gene Therapy Needs Most in the Current Moment

CGTLive®’s Weekly Rewind – December 19, 2025

Steven W. Pipe, MD, on the Implications of the Final Data From Hemgenix’s HOPE-B Trial